10-Q: Milestone Scientific Reports Q3 2024 Results, Revenue Mixed Amidst Strategic Shifts

Milestone Scientific's Q3 2024 results show a mixed performance with increased revenue offset by continued operating losses, as the company navigates strategic shifts in distribution and product development.

Summary

• Milestone Scientific reported a net loss of $1.46 million for the third quarter of 2024, consistent with the $1.47 million loss in the same period of 2023.
• The company's product sales increased to $2.51 million in Q3 2024 from $2.06 million in Q3 2023, driven by higher international sales.
• For the nine months ended September 30, 2024, the net loss was $2.68 million, compared to $5.02 million for the same period in 2023.
• Year-to-date product sales were $6.62 million, down from $7.57 million in the prior year, with a decrease in international sales partially offset by growth in e-commerce.
• The company's cash and cash equivalents stood at $4.78 million as of September 30, 2024, with working capital of approximately $6.9 million.
• Milestone Scientific sold New Jersey net operating losses for $2.0 million in April 2024, which contributed to a reduction in the year-to-date net loss.
• The company is actively pursuing positive cash flow through increased revenue and reduced operating expenses.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as increased sales in Q3, regulatory approvals, and strategic partnerships, the company continues to experience operating losses and faces risks related to its manufacturing and distribution arrangements. The need for additional capital raises concerns about the company's long-term financial stability.

Positives

• Product sales increased in Q3 2024 compared to Q3 2023, driven by higher international sales and growth in e-commerce.
• The company's year-to-date net loss improved significantly due to a one-time gain from the sale of net operating losses.
• Milestone Scientific secured regulatory approval for its CompuFlo Epidural System in Brazil, expanding its market reach.
• The strategic partnership with Axial Biologics is expected to enhance distribution of the CompuFlo Epidural System.
• The company received multiple patent allowances, strengthening its intellectual property portfolio.
• The company's cash position improved due to the sale of marketable securities and the sale of net operating losses.

Negatives

• The company continues to experience operating losses, with a net loss of $1.46 million in Q3 2024.
• Year-to-date product sales decreased compared to the same period in 2023, primarily due to lower international sales.
• The company recorded no revenue from China for the three and nine months ended September 30, 2024.
• The company relies on informal manufacturing agreements with third parties, which could pose a risk to production.
• The company has a history of operating losses and may need to raise additional capital to continue operations.

Risks

• The company's continued operations depend on its ability to raise additional capital until it achieves profitability.
• Milestone Scientific relies on third-party manufacturers, and any disruption to these relationships could negatively impact production.
• The company faces risks related to international sales and operations, including potential disruptions in distribution channels.
• Changes in distribution arrangements could expose the company to risks of interruption of marketing efforts.
• The company's products may become obsolete or non-competitive due to developments by competitors.
• The company's net operating losses may be subject to limitations, potentially expiring before they can be utilized.

Future Outlook

The company's financial forecasts indicate that its current cash and liquidity are sufficient to finance operating requirements for at least the next 12 months. Milestone Scientific is actively pursuing positive cash flow through increased revenue and reduced operating expenses, but its continued operations depend on its ability to raise additional capital until it achieves profitability.

Management Comments

• Management has prepared financial forecasts covering a period of 12 months from the date of issuance of these financial statements.
• Management believes that the company's current cash and liquidity is sufficient to finance the operating requirements for at least the next 12 months from the filing date.
• Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses.

Industry Context

Milestone Scientific operates in the biomedical technology sector, focusing on innovative injection technologies for medical and dental use. The company's focus on computer-controlled injection devices aligns with the industry trend towards more precise and patient-friendly medical procedures. The company's expansion into the medical market with the CompuFlo Epidural System reflects a broader trend of medical device companies diversifying their product portfolios. The company's strategic partnerships and regulatory approvals are crucial for its growth in a competitive market.

Comparison to Industry Standards

• Milestone Scientific's revenue growth in the dental segment is mixed, with a decrease in year-to-date sales compared to the previous year, while the medical segment is showing early signs of growth.
• Compared to other medical device companies, Milestone Scientific's operating losses are significant, highlighting the challenges of commercializing new medical technologies.
• The company's reliance on third-party manufacturers is a common practice in the industry, but it also introduces risks that need to be managed effectively.
• The company's e-commerce strategy is a positive step, aligning with the trend of direct-to-consumer sales in the medical and dental industries.
• The company's patent portfolio is a key asset, providing a competitive advantage in the market.
• The company's recent regulatory approvals in Brazil and the US are positive developments, but the company needs to demonstrate consistent revenue growth to achieve profitability.

Management Changes

Related Party Transactions

• Milestone Scientific has a supply agreement with United Systems, whose controlling shareholder is a significant stockholder of Milestone Scientific.
• The Director of Clinical Affairs receives royalty fees and consulting fees from Milestone Scientific.
• Leonard Osser, a director, has a Royalty Sharing Agreement with the company.
• Dr. D. Demesmin, a board member, is the CEO of the University Pain Medicine Center (STEMMEE), which purchases products from the company.

Stakeholder Impact

• Shareholders may be concerned about the company's continued operating losses and the need for additional capital raises.
• Employees may be affected by the company's strategic shifts and potential restructuring.
• Customers may benefit from the company's innovative products and expanded distribution channels.
• Suppliers may be impacted by changes in the company's manufacturing and supply chain arrangements.
• Creditors may be concerned about the company's financial stability and ability to repay debts.

Next Steps

• Milestone Scientific will continue to focus on expanding its global footprint for the CompuFlo Epidural and CathCheck System.
• The company will continue to pursue the generation of positive cash flows from operating activities.
• Milestone Scientific will continue to develop and commercialize its DPS Dynamic Pressure Sensing technology platform.
• The company will continue to work with medical facilities and device distributors to develop new channels of distribution.

Key Dates

Keywords

Milestone Scientific, CompuFlo Epidural System, STA Single Tooth Anesthesia System, dental, medical devices, anesthesia, e-commerce, international sales, patents, regulatory approval